156 related articles for article (PubMed ID: 25199680)
41. Lamivudine prophylaxis for hepatitis B virus carrier patients with breast cancer during adjuvant chemotherapy.
Lee HJ; Kim DY; Keam B; Lee JH; Han SW; Oh DY; Yoon JH; Kim TY; Kim YJ; Lee KW; Kim JW; Jeong SH; Lee JS; Kim JH; Im SA
Breast Cancer; 2014 Jul; 21(4):387-93. PubMed ID: 23073741
[TBL] [Abstract][Full Text] [Related]
42. Preventing chemotherapy-induced hepatitis B reactivation in breast cancer patients: a prospective comparison of prophylactic versus deferred preemptive lamivudine.
Tsai SH; Dai MS; Yu JC; Ho CL; Chen YC; Wu YY; Chang PY; Kao WY; Chao TY
Support Care Cancer; 2011 Nov; 19(11):1779-87. PubMed ID: 20927554
[TBL] [Abstract][Full Text] [Related]
43. Risk of hepatitis B reactivation in HBsAg-negative/HBcAb-positive patients with undetectable serum HBV DNA after treatment with rituximab for lymphoma: a meta-analysis.
Tang Z; Li X; Wu S; Liu Y; Qiao Y; Xu D; Li J
Hepatol Int; 2017 Sep; 11(5):429-433. PubMed ID: 28856548
[TBL] [Abstract][Full Text] [Related]
44. Reactivation of hepatitis B virus infection with cytotoxic therapy in non-Hodgkin's lymphoma.
Ozguroglu M; Bilici A; Turna H; Serdengecti S
Med Oncol; 2004; 21(1):67-72. PubMed ID: 15034216
[TBL] [Abstract][Full Text] [Related]
45. Hepatitis B virus reactivation and role of antiviral prophylaxis in lymphoma patients with past hepatitis B virus infection who are receiving chemoimmunotherapy.
Koo YX; Tan DS; Tan IB; Tao M; Chow WC; Lim ST
Cancer; 2010 Jan; 116(1):115-21. PubMed ID: 19899164
[TBL] [Abstract][Full Text] [Related]
46. Hepatitis B virus reactivation in patients receiving chemotherapy for cancer treatment: role of Lamivudine prophylaxis.
Coiffier B
Cancer Invest; 2006; 24(5):548-52. PubMed ID: 16939967
[TBL] [Abstract][Full Text] [Related]
47. Fatal reactivation of hepatitis B virus in a patient who was hepatitis B surface antigen negative and core antibody positive before receiving chemotherapy for non-Hodgkin lymphoma.
Wu JM; Huang YH; Lee PC; Lin HC; Lee SD
J Clin Gastroenterol; 2009; 43(5):496-8. PubMed ID: 19247200
[TBL] [Abstract][Full Text] [Related]
48. Chemotherapy-induced hepatitis B reactivation in lymphoma patients with resolved HBV infection: a prospective study.
Hsu C; Tsou HH; Lin SJ; Wang MC; Yao M; Hwang WL; Kao WY; Chiu CF; Lin SF; Lin J; Chang CS; Tien HF; Liu TW; Chen PJ; Cheng AL;
Hepatology; 2014 Jun; 59(6):2092-100. PubMed ID: 24002804
[TBL] [Abstract][Full Text] [Related]
49. Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab.
Yeo W; Chan TC; Leung NW; Lam WY; Mo FK; Chu MT; Chan HL; Hui EP; Lei KI; Mok TS; Chan PK
J Clin Oncol; 2009 Feb; 27(4):605-11. PubMed ID: 19075267
[TBL] [Abstract][Full Text] [Related]
50. The Effect of Prophylactic Lamivudine plus Adefovir Therapy Compared with Lamivudine Alone in Preventing Hepatitis B Reactivation in Lymphoma Patients with High Baseline HBV DNA during Chemotherapy.
Cai Q; Chen K; Chen J; Wu S; Geng Q; Huang H; Lin T; Jiang W; Xia Z; Duan H; Rao H; Yao M; Hu L
PLoS One; 2016; 11(10):e0164210. PubMed ID: 27711135
[TBL] [Abstract][Full Text] [Related]
51. The impact of hepatitis B virus (HBV) infection on clinical outcomes of patients with diffuse large B-cell lymphoma.
Law MF; Lai HK; Chan HN; Ha CY; Ng C; Yeung YM; Yip SF
Eur J Cancer Care (Engl); 2015; 24(1):117-24. PubMed ID: 25848698
[TBL] [Abstract][Full Text] [Related]
52. The effectiveness of lamivudine in preventing hepatitis B viral reactivation in rituximab-containing regimen for lymphoma.
He YF; Li YH; Wang FH; Jiang WQ; Xu RH; Sun XF; Xia ZJ; Huang HQ; Lin TY; Zhang L; Bao SP; He YJ; Guan ZZ
Ann Hematol; 2008 Jun; 87(6):481-5. PubMed ID: 18299831
[TBL] [Abstract][Full Text] [Related]
53. Lamivudine therapy for chemotherapy-induced reactivation of hepatitis B virus infection.
Ahmed A; Keeffe EB
Am J Gastroenterol; 1999 Jan; 94(1):249-51. PubMed ID: 9934765
[TBL] [Abstract][Full Text] [Related]
54. Hepatitis B virus reactivation in patients with resolved hepatitis B virus infection receiving chemotherapy or immunosuppressive therapy.
Su YC; Lin PC; Yu HC; Wu CC
Eur J Gastroenterol Hepatol; 2018 Aug; 30(8):925-929. PubMed ID: 29621049
[TBL] [Abstract][Full Text] [Related]
55. A Comparison of Entecavir and Lamivudine for the Prophylaxis of Hepatitis B Virus Reactivation in Solid Tumor Patients Undergoing Systemic Cytotoxic Chemotherapy.
Chen WC; Cheng JS; Chiang PH; Tsay FW; Chan HH; Chang HW; Yu HC; Tsai WL; Lai KH; Hsu PI
PLoS One; 2015; 10(6):e0131545. PubMed ID: 26121480
[TBL] [Abstract][Full Text] [Related]
56. Risk of hepatitis B virus (HBV) reactivation in hepatitis B surface antigen negative/hepatitis B core antibody positive patients receiving rituximab-containing combination chemotherapy without routine antiviral prophylaxis.
Koo YX; Tay M; Teh YE; Teng D; Tan DS; Tan IB; Tai DW; Quek R; Tao M; Lim ST
Ann Hematol; 2011 Oct; 90(10):1219-23. PubMed ID: 21520001
[TBL] [Abstract][Full Text] [Related]
57. Meta-analysis of prophylactic entecavir or lamivudine against hepatitis B virus reactivation.
Yang C; Qin B; Yuan Z; Chen L; Zhou HY
Ann Hepatol; 2016; 15(4):501-11. PubMed ID: 27236149
[TBL] [Abstract][Full Text] [Related]
58. [Hepatitis B virus reactivation after cessation of prophylactic lamivudine therapy in B-cell lymphoma patients treated with rituximab combined CHOP therapy].
Mimura N; Tsujimura H; Ise M; Sakai C; Kojima H; Fukai K; Yokosuka O; Takagi T; Kumagai K
Rinsho Ketsueki; 2009 Dec; 50(12):1715-9. PubMed ID: 20068280
[TBL] [Abstract][Full Text] [Related]
59. Antiviral efficacy analysis of telbivudine concurrent with the first cycle of chemotherapy in HBsAg-positive lymphoma patients.
Li W; Huang L; Guo H; Wei X; Liang Z
J Clin Virol; 2014 Oct; 61(2):199-203. PubMed ID: 25128391
[TBL] [Abstract][Full Text] [Related]
60. Prophylactic use of lamivudine for hepatitis B exacerbation in post-operative breast cancer patients receiving anthracycline-based adjuvant chemotherapy.
Yun J; Kim KH; Kang ES; Gwak GY; Choi MS; Lee JE; Nam SJ; Yang JH; Park YH; Ahn JS; Im YH
Br J Cancer; 2011 Feb; 104(4):559-63. PubMed ID: 21285992
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
